Transcripts

Madrigal Pharmaceuticals (MDGL) earnings call transcripts

Earnings call transcripts for Madrigal Pharmaceuticals, Inc., with a summary, the guidance given, and what analysts pressed on.

Open MDGL in Gloom →
Madrigal Pharmaceuticals' chart, financials and news, free in your browser.Open MDGL in Gloom →
  • Q2 2026 earnings call

    Management framed Resmetirom as the foundational MASH therapy, emphasizing durable launch momentum, market expansion and a combination-focused pipeline while avoiding a firm F4C readout date.

    Jul 30, 2026Confident0.78